Previous 10 | Next 10 |
Ashford Hospitality Trust (AHT) -21% on update of exchange offers for all outstanding series of preferred stock.BioLineRx (BLRX) -13% on Q3 earnings release.AIM ImmunoTech (AIM) -8% after AIM and Shionogi terminated their material transfer agreement.Niu Technologies (...
OCALA, Fla., Nov. 13, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today provided a business update for the third q...
OCALA, Fla., Nov. 02, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announced today the publication of statistically significant data detailing how its drug Ampligen could have a considerable positive impact on people living with the debilitating illness myalgic encephal...
TAMPA, Fla. and OCALA, Fla., Oct. 30, 2020 (GLOBE NEWSWIRE) -- BioFlorida has announced Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech Inc. (NYSE American: AIM), as its Weaver H. Gaines Entrepreneur of the Year. The Entrepreneur of the Year Award recognizes an entrepreneur who ...
AIM ImmunoTech reports IRB go ahead for AMP-511 clinical trial. Vir Biotechnology reports positive data for VIR-2482 influenza A treatment. CRISPR Therapeutics reports positive CARBON trial for CD19+ B-cell malignancies. For further details see: AIM Trial Moves Ahead, An...
OCALA, Fla. , Oct. 22, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, is scheduled to participate in a virtual panel titled, “COVID-19: Progress on Treatments & Prevention”...
The independent Institutional Review Board has granted approval to AIM ImmunoTech ([[AIM]] +3.8%) to widen the trial for its drug candidate Ampligen and include people suffering from long-term effects of the coronavirus (COVID-19).The group, known as COVID-19 ‘lon...
OCALA, Fla., Oct. 06, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) is pleased to announce that it has received Institutional Review Board (IRB) approval for the expansion of the AMP-511 Expanded Access Program (EAP) clinical trial for Myalgic Encephalomyelitis/Chronic F...
Looking For Penny Stocks To Buy? Buying penny stocks can be a high-risk endeavor for any trader. However, the rewards can be sweet. Considering that you’ve got a lot of headwinds going into a trade, it’s important to research, first. It’s also important to outli...
Kubient KBNT -21% on Q2 2020 Results Earnings call.Nikola NKLA -12% after WSJ warns on stalled talks with potential partners.NanoVibronix (NAOV) -10%.Golar LNG (GLNG) -9%.Digital Ally (DGLY) -8%.DiamondPeak Holdings (DPHC) -8%.AIM ImmunoTech (AIM) -7%.Pen...
News, Short Squeeze, Breakout and More Instantly...
OCALA, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of new pre-clinical data concerning the company’s drug Ampligen as part of a combinational therapy in the...
OCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Pitch Con...
OCALA, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Lunch Break Series ...